(VIANEWS) – Shares of BIOSENIC (BEL 20: BIOS.BR) dropped by a staggering 27.01% in 21 sessions from €0.14 to €0.10 at 05:13 EST on Thursday, after four successive sessions in a row of losses. BEL 20 is falling 0.79% to €3,795.60, after two consecutive sessions in a row of losses.
About BIOSENIC
BioSenic S.A., a biotech company, focuses on developing clinical assets. Its technologies include cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced mesenchymal stromal cells, which can be stored at the point of use in the hospital; and Arsenic TriOxide platform for use in immuno-oncology to treat graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. The company's investigational medicinal product is ALLOB, which is in a Phase IIb clinical trial in patients with difficult tibial fractures. The company is based in Mont-Saint-Guibert, Belgium.
Earnings Per Share
As for profitability, BIOSENIC has a trailing twelve months EPS of €-0.35.
Volatility
BIOSENIC’s last week, last month’s, and last quarter’s current intraday variation average was a negative 5.16%, a negative 1.15%, and a positive 5.90%.
BIOSENIC’s highest amplitude of average volatility was 5.16% (last week), 2.83% (last month), and 5.90% (last quarter).
More news about BIOSENIC (BIOS.BR).
